Physician profile
Lev Borukhov
NPI 1801614664
$1,034.10
in general payments reported to CMS, 2019-2025
12 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $320.89 | 2025 | Korlym |
| Amgen INC. | $125.00 | 2025 | Tepezza |
| Lilly USA, LLC | $117.88 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $87.76 | 2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $86.09 | 2025 | Symbravo |
| Intra-Sana Laboratories | $78.42 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Amneal Pharmaceuticals LLC | $55.24 | 2025 | Unithroid |
| Tandem Diabetes Care, INC. | $45.55 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $40.68 | 2025 | |
| Insulet Corporation | $28.48 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.28 | 2025 | Jardiance |
| Averitas Pharma INC. | $20.83 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Borukhov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.